Prostatic Hyperplasia: Clinical Trials

64 trials for Prostatic Hyperplasia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

64 completed. 64 Phase 3, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 364Completed 64
Phase 28Completed 8

Follow Prostatic Hyperplasia: new trials by email Literature Review of Prostatic Hyperplasia trials Research Report on Prostatic Hyperplasia

Trials (filtered) newest first · largest first

All 64 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of DKF-313 in Patients With Benign Prostatic Hyperplasia
DKF-313, Dutasteride, Tadalafil - Benign Prostatic Hyperplasia
Phase 3CompletedDongkook Pharmaceutical Co., Ltd.6672021-07-272023-09-21
The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility
Spermotrend - Male Infertility, Benign Prostatic Hyperplasia
Phase 2 / Phase 3CompletedCatalysis SL1502021-06-152023-03-28
Efficacy and Safety of Tanzânia Association in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia
Tanzânia association, Omnic Ocas, Omnic Ocas placebo - Erectile Dysfunction, Benign Prostatic Hyperplasia
Phase 3CompletedEMS2952021-03-142025-12-08
Composite Steep-pulseTreatment Device Used in Patients With Benign Prostatic Hyperplasia
Composite Steep-pulse Treatment Device, Tamsulosin Hydrochloride Capsules - Benign Prostatic Hyperplasia
Phase 2 / Phase 3CompletedREMD Medical Technology1602020-08-202022-09-07
A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial A Comparison of Traditional and MOSES Laser Enucleation of the Prostate (MOLEP): A Prospective, Randomized, Double-blinded Control Trial
Moses laser enucleation of prostate - Benign Prostatic Hyperplasia
Phase 3CompletedVanderbilt University Medical Center602020-01-012022-03-31
Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)
GV1001 placebo, Proscar placebo - Benign Prostatic Hyperplasia (BPH)
Phase 3CompletedGemVax & Kael4232019-10-302022-08-25
Extension Study of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia
Vibegron - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH2762019-09-192024-08-21
Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)
Vibegron, Placebo - Overactive Bladder
Phase 3CompletedUrovant Sciences GmbH11052019-03-262024-08-07
HoLEP Vs BPEP for Large Prostatic Adenoma
Holmium laser enucleation of the prostate versus bipolar transurethral enucleation of the prostate in management of benign prostatic hyperplasia - Prostate Hyperplasia
Phase 3CompletedAhmed Maher Gamil Ahmed Higazy1002018-02-012020-06-16
Prostatic Artery Embolization Versus Medical Treatment in Symptomatic Benign Prostatic Hyperplasia
Embosphere® (Prostatic Arteries Embolization), Drug therapy - Benign Prostatic Hyperplasia
Phase 3CompletedAssistance Publique - Hôpitaux de Paris902016-08-012022-05-03
Efficacy Study of Fedovapagon for Nocturia in Men With Benign Prostatic Hyperplasia (BPH)
Fedovapagon 2 mg, Placebo - Nocturia
Phase 2 / Phase 3CompletedVantia Ltd4322016-03-012018-10-31
Clinical Trial to Compare the Solifenacin/Tamsulosin Combination Therapy With Tamsulosin Monotherapy for LUTS Due to BPH
Tamsulosin 0.2mg + Solifenacin 5mg, Tamsulosin 0.2mg + Placebo(Solifenacin) - Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
Phase 3CompletedJeil Pharmaceutical Co., Ltd.7802016-02-012019-08-29
Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients
Tamsulosin 0.2mg, Tadalafil 5mg - Benign Prostatic Hyperplasia
Phase 3CompletedChong Kun Dang Pharmaceutical4552015-09-012017-08-11
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
HCP1303 capsule 5/0.2mg, HCP1303 capsule 5/0.4mg, HGP1201 - Benign Prostatic Hyperplasia
Phase 3CompletedHanmi Pharmaceutical Company Limited5102015-03-012016-10-13
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
Placebo, HGP0412 capsule, HIP1402 capsule - Benign Prostate Hyperplasia
Phase 3CompletedHanmi Pharmaceutical Company Limited4942014-10-012016-10-13
Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS
Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg - Benign Prostatic Hyperplasia
Phase 3CompletedGL Pharm Tech Corporation3092014-03-012016-02-25
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
Dutasteride 0.5mg capsules, Dutasteride placebo capsules, Tamsulosin 0.2mg tablets - Prostatic Hyperplasia
Phase 3CompletedGlaxoSmithKline6072014-02-102019-04-05
Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH
PRX302, Placebo - Benign Prostatic Hyperplasia
Phase 3CompletedSophiris Bio Corp4792013-10-012017-04-27
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
5 mg Tadalafil, Placebo, 0.2 mg Tamsulosin - Benign Prostate Hyperplasia, Erectile Dysfunction
Phase 3CompletedEli Lilly and Company9092013-09-012017-06-20
Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)(NX02-0022)
NX-1207 - Benign Prostatic Hyperplasia, BPH
Phase 3CompletedNymox Corporation1602013-04-012017-03-10

Showing 20 of 64. Sign in to see all of them.

Narrower conditions

Lower Urinary Tract Symptoms (10)  ·  Erectile Dysfunction (3)  ·  Prostatic Neoplasms (2)  ·  Urinary Bladder Neck Obstruction (2)  ·  Urinary Bladder, Overactive (2)  ·  Genital Diseases, Male (1)  ·  Hyperplasia (1)  ·  Infertility, Male (1)  ·  Metabolic Syndrome (1)  ·  Neoplasms (1)  ·  Nocturia (1)  ·  Prostatic Diseases (1)  ·  Prostatitis (1)  ·  Sexual Dysfunction, Physiological (1)

Broader conditions

Genital Diseases (64)  ·  Male Urogenital Diseases (64)  ·  Urogenital Diseases (64)  ·  Genital Diseases, Male (63)  ·  Prostatic Diseases (63)  ·  Pathological Conditions, Signs and Symptoms (15)  ·  Signs and Symptoms (14)  ·  Urological Manifestations (14)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Urologic Diseases (6)  ·  Lower Urinary Tract Symptoms (4)  ·  Urinary Bladder Diseases (4)  ·  Mental Disorders (3)  ·  Sexual Dysfunction, Physiological (3)

Interventions

Tamsulosin (13)  ·  Tadalafil (12)  ·  Dutasteride (5)  ·  Finasteride (4)  ·  alfuzosin (4)  ·  fexapotide (4)  ·  silodosin (4)  ·  Solifenacin Succinate (3)  ·  N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide (2)  ·  Biofeedback, Psychology (1)  ·  Botulinum Toxins, Type A (1)  ·  Doxazosin (1)  ·  Drug Therapy (1)  ·  Duration of Therapy (1)  ·  Levofloxacin (1)

Sponsors

Eli Lilly and Company (10)  ·  GlaxoSmithKline (5)  ·  Sanofi (5)  ·  Health Ever Bio-Tech Co., Ltd. (4)  ·  Nymox Corporation (4)  ·  Watson Pharmaceuticals (3)  ·  AEterna Zentaris (2)  ·  Astellas Pharma Europe B.V. (2)  ·  Hanmi Pharmaceutical Company Limited (2)  ·  National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2)  ·  Urovant Sciences GmbH (2)  ·  Aberdeen Royal Infirmary (1)  ·  Ahmed Maher Gamil Ahmed Higazy (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  CMX Research (1)

Countries

United States (26)  ·  Italy (11)  ·  Canada (9)  ·  France (9)  ·  South Korea (9)  ·  Germany (8)  ·  Poland (8)  ·  Belgium (6)  ·  Japan (6)  ·  Mexico (6)  ·  Netherlands (6)  ·  Russia (6)  ·  United Kingdom (6)  ·  Greece (5)  ·  Taiwan (5)

Top investigators

Allan J Pantuck, MD, MS, FACS (2)  ·  Lawrence Hill, PharmD, RPh (2)  ·  Andrew Avins, MD, MPH (1)  ·  Cathryn Glazener, MD (1)  ·  Choung-Soo Kim, M.D.,Ph.D (1)  ·  Christopher Re Chapple, BSc MD (1)  ·  Claus Roehrborn (1)

Results publications

PMID 26299520, PMID 21135869, PMID 23234617, PMID 11796283, PMID 12689743, PMID 12893330, PMID 14681504, PMID 16467543, PMID 16536764, PMID 18355417, PMID 18722631, PMID 19371887, PMID 19409693, PMID 19815265, PMID 20163842, PMID 21109344, PMID 21871706, PMID 22017520, PMID 22297243, PMID 23346990, PMID 24119319, PMID 24571205, PMID 24938580, PMID 25353053, PMID 25712312, PMID 26945662, PMID 29383480, PMID 29490509, PMID 30680237, PMID 37070660, PMID 37415648, PMID 40683564, PMID 41363221

NIH funding

2008 (2), 2018 (2), R01DK056199 (1), U01DK046472 (1)